The role of osimertinib/osimertinib

Osimertinib (Osimertinib) is a targeted therapy drug mainly used to treat advanced non-small cell lung cancer (NSCLC), especially patients with positive EGFR (epidermal growth factor receptor) mutations. EGFRMutation is a common molecular marker of lung cancer and is associated with tumor growth, spread and drug resistance. Osimertinib/Osimertinib blocks the growth signaling of tumor cells by inhibiting EGFR kinase activity, thereby inhibiting the growth and spread of tumors. Compared with traditional chemotherapy drugs, Osimertinib/Osimertinib has higher selectivity and lower toxic side effects. It can significantly extend the progression-free survival and overall survival of patients, and improve the treatment effect and quality of life. Osimertinib/The targeting effect of Osimertinib enables it to act on tumor cells more accurately, reduce damage to normal cells, and also reduce the toxic and side effects of the drug. Therefore, Osimertinib/Osimertinib has become the first-line treatment for patients with EGFR mutation-positive NSCLC and has brought new treatment hope to these patients.